Semaglutide (GLP-1)
The original GLP-1 receptor agonist — the reference compound in metabolic research, now also available as an oral capsule and as a co-formulation with BPC-157.
For gut-focused protocols in particular, oral is not a compromise — it is the point. BPC-157 and KPV both act on mucosal tissue, and Prime supplies both as capsules alongside the vial. The rest of this list is small molecules that were always oral: rapamycin, MK-677, tesofensine, fenbendazole, dihexa.
The original GLP-1 receptor agonist — the reference compound in metabolic research, now also available as an oral capsule and as a co-formulation with BPC-157.
Small-molecule NNMT inhibitor investigated for its role in adipocyte metabolism and NAD+ salvage. 50mg, 30 capsules.
ERR agonist studied as an exercise mimetic — one of the more interesting recent additions to metabolic research. 350mcg, 60 capsules.
Triple monoamine reuptake inhibitor studied for appetite regulation. 500mcg and 1mg capsule strengths.
Tight-junction regulator studied specifically for intestinal permeability. 350mcg, 60 capsules.
Orally active ghrelin mimetic — no injection, no reconstitution. 10mg and 25mg capsules.
Benzimidazole studied for microtubule dynamics. Capsule format.